Inovio Pharmaceuticals Investors Face Deadline in Securities Class Action
Investors who purchased Inovio Pharmaceuticals, Inc. (NASDAQ: INO) securities between October 10, 2023, and December 26, 2025, may be eligible to participate in a securities class action lawsuit. A lead plaintiff deadline of April 7, 2026, has been set for those wishing to take a leading role in the litigation.
What’s at Stake? Allegations of Misleading Statements
The lawsuit alleges that Inovio Pharmaceuticals made false and/or misleading statements regarding its CELLECTRA device manufacturing and the timeline for submitting its INO-3107 Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA). Specifically, the claim is that the company lacked sufficient information to justify accelerated approval or priority review for INO-3107, and that its overall regulatory and commercial prospects were overstated.
Who is Rosen Law Firm?
Rosen Law Firm, a global investor rights law firm, is leading the charge in this case. They specialize in securities class actions and shareholder derivative litigation, representing investors worldwide. The firm highlights its track record of success, including achieving the largest ever securities class action settlement against a Chinese Company and consistently ranking among the top firms in the field. They were ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.
What Does This Mean for Investors?
If you purchased Inovio securities during the specified Class Period, you may be entitled to compensation without incurring out-of-pocket fees or costs, through a contingency fee arrangement. A lead plaintiff directs the litigation on behalf of other class members.
Navigating Securities Class Action Lawsuits: A Growing Trend
Securities class action lawsuits are becoming increasingly common, reflecting a heightened focus on corporate accountability and investor protection. These lawsuits often arise when companies are accused of misleading investors about their financial performance or business prospects. The Inovio case is part of this broader trend.
The Role of “Middlemen” Law Firms
Rosen Law Firm emphasizes the importance of selecting qualified counsel with a proven track record. They caution investors to be wary of firms that act merely as “middlemen,” referring clients to other firms that actually litigate the cases. This highlights a potential pitfall for investors seeking legal representation.
Contingency Fee Arrangements: How They Work
Contingency fee arrangements are standard in securities class action lawsuits. Which means investors do not pay legal fees upfront. Instead, the law firm receives a percentage of any recovery obtained through settlement or judgment. This arrangement makes legal representation accessible to a wider range of investors.
Key Dates and How to Participate
The crucial date to remember is April 7, 2026. Here’s the deadline for investors who wish to move the Court to serve as lead plaintiff. To join the Inovio class action, you can visit https://rosenlegal.com/submit-form/?case_id=52847, call Phillip Kim, Esq. Toll-free at 866-767-3653, or email [email protected].
FAQ
Q: What is a lead plaintiff?
A: A lead plaintiff is a representative party who directs the litigation on behalf of other class members.
Q: Do I have to be the lead plaintiff to benefit from the lawsuit?
A: No, an investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Q: What are the costs involved in joining the class action?
A: You may be entitled to compensation without payment of any out-of-pocket fees or costs through a contingency fee arrangement.
Q: Is a class already certified?
A: No, a class has not yet been certified. You are not represented by counsel unless you retain one.
Did you realize? Rosen Law Firm has recovered hundreds of millions of dollars for investors.
Follow Rosen Law Firm on LinkedIn, Twitter, and Facebook for updates.
Pro Tip: Carefully consider your options and consult with legal counsel before making any decisions regarding your participation in this class action.
To learn more about this case and your potential rights, visit Rosen Law Firm’s website or contact Phillip Kim, Esq. Directly.
